Department of Radiology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 5650871, Japan.
Eur J Radiol. 2011 Dec;80(3):643-7. doi: 10.1016/j.ejrad.2010.08.037. Epub 2010 Sep 23.
To investigate the validity of determining the contrast medium dose based on body surface area (BSA) for the abdominal contrast-enhanced multi-detector row CT comparing with determining based on body weight (BW).
Institutional review committee approval was obtained. In this retrospective study, 191 patients those underwent abdominal contrast-enhanced multi-detector row CT were enrolled. All patients received 96 mL of 320 mg I/mL contrast medium at the rate of 3.2 mL. The iodine dose required to enhance 1 HU of the aorta at the arterial phase and that of liver parenchyma at portal venous phase per BSA were calculated (EUBSA) and evaluated the relationship with BSA. Those per BW were also calculated (EUBW) and evaluated. Estimated enhancement values (EEVs) of the aorta and liver parenchyma with two protocols for dose decision based on BSA and BW were calculated and patient-to-patient variability was compared between two protocols using the Levene test.
The mean of EUBSA and EUBW were 0.0621 g I/m2/HU and 0.00178 g I/kg/HU for the aorta, and 0.342 g I/m2/HU and 0.00978 g I/kg/HU for the liver parenchyma, respectively. In the aortic enhancement, EUBSA was almost constant regardless of BSA, and the mean absolute deviation of the EEV with the BSA protocol was significantly lower than that with the BW protocol (P<.001), although there was no significant difference between two protocols in the hepatic parenchymal enhancement (P=.92).
For the aortic enhancement, determining the contrast medium dose based on BSA was considered to improve patient-to-patient enhancement variability.
探讨基于体表面积（BSA）与基于体重（BW）确定腹部对比增强多层 CT 对比剂剂量的有效性。
本研究获得了机构审查委员会的批准。回顾性分析 191 例行腹部增强多层 CT 检查的患者。所有患者均以 3.2 mL/s 的速度经外周静脉团注 96 mL 浓度为 320 mg I/mL 的对比剂。计算动脉期主动脉每增强 1 HU 和门静脉期肝实质每增强 1 HU 所需的碘剂量（EUBSA），并评估其与 BSA 的关系。计算基于 BW 的相应剂量（EUBW）并进行评估。计算基于 BSA 和 BW 两种方案决定剂量时主动脉和肝实质的估计增强值（EEV），采用 Levene 检验比较两种方案之间患者间的变异性。
主动脉的 EUBSA 和 EUBW 的平均值分别为 0.0621 g I/m2/HU 和 0.00178 g I/kg/HU，肝实质的 EUBSA 和 EUBW 的平均值分别为 0.342 g I/m2/HU 和 0.00978 g I/kg/HU。在主动脉增强方面，EUBSA 几乎与 BSA 无关，基于 BSA 方案的 EEV 平均绝对偏差显著低于基于 BW 方案（P<.001），尽管两种方案在肝实质增强方面无显著差异（P=.92）。
对于主动脉增强，基于 BSA 确定对比剂剂量可改善患者间增强变异性。
